A Platform for Synthesis of Stable Peptide Therapeutics

Enzymatic Peptide Cross-Linking Technology to Redefine Therapeutic Peptide Design

Sethera Therapeutics

Sethera is revolutionizing peptide-based drug development with our cutting-edge enzymatic cross-linking technology.

Our platform enables the synthesis of highly stable, polymacrocyclic peptides designed to engage multiple targets simultaneously, offering unparalleled precision in therapeutic design.

By harnessing the power of natural enzymatic processes, we create complex peptide structures that maintain their integrity in physiological conditions, paving the way for innovative treatments for cancer and other challenging diseases.

Our technology not only enhances the stability and efficacy of peptide therapeutics but occurs at biological pH in aqueous solutions, enabling high throughput screening.

We are opening new possibilities for targeting heterogeneous and complex diseases with multivalent and multifunctional peptides.

Services

Applications

Sethera Therapeutics’ polymacrocyclic peptides are designed to interact with complex biological surfaces, offering a powerful new approach to targeting challenging biological systems. These advanced peptides enable the precise modulation of intricate biological pathways, opening the door to innovative treatments across a wide range of therapeutic areas.

Technology

Our technology at Sethera Therapeutics revolves around the enzymatic generation of unique peptide architectures, capable of maintaining stability and functionality under physiological conditions. We are continuously expanding our enzymatic repertoire to create even more options for sophisticated peptide structures, enhancing our ability to address diverse and complex biological challenges.

Partnerships

Sethera Therapeutics is seeking partners interested in leveraging our peptide architectures to screen their biological targets. By collaborating with industry leaders and research institutions, we aim to unlock new possibilities in drug discovery and development, providing tailored solutions for a wide array of therapeutic needs.

Innovations and Vision

Architectures

Our platform enables the creation of diverse peptide architectures, including cross-links to sidechains or to the end of a peptide, multiple in-line cross-links and nested cross-links, repeatable polymacrocyclization within a single peptide, and complex intra- and inter-peptide structures. These advanced designs provide unprecedented control over peptide stability and functionality, tailored to meet specific therapeutic challenges.

Future

We are advancing toward the development of polymacrocyclic peptides capable of engaging multiple targets simultaneously, while also allowing for the conjugation of multiple therapeutic payloads. This next-generation technology aims to revolutionize multi-targeted therapies and expand the possibilities for precision medicine.

CEO

Karsten Eastman

Dr. Eastman received a PhD from the University of Utah under the mentorship of Professor Vahe Bandarian, where they discovered the key processes that enable Sethera Therapeutics’ innovative technology.

As a co-founder of Sethera, Dr. Eastman is leading the company’s efforts to commercialize cutting-edge peptide therapeutics, drawing on their experience in enzyme and peptide research, patent development, and engagement with key business mentors.

CSO and President

Vahe Bandarian

Professor Vahe Bandarian is a distinguished faculty member and Associate Dean at the University of Utah, recognized for his exceptional contributions to the field of chemistry. He is a Fellow of the American Chemical Society (ACS), the American Association for the Advancement of Science (AAAS), and the American Society for Biochemistry and Molecular Biology (ASBMB).

His groundbreaking research has earned him the prestigious Pfizer Award in Enzyme Chemistry from the ACS and the Distinguished Research Award from the University of Utah.

Our Office

Sethera Therapeutics

48 S Rio Grande St
Salt Lake City, UT 84101